Author: healthadmin

A study led by Weill Cornell Medicine and NewYork-Presbyterian researchers has found that mysterious circulating tumor cells called double-positive (DP) cells are associated with shorter survival times in patients with advanced breast cancer. This finding highlights the potential importance of these poorly studied cells in breast cancer progression. Circulating tumor cells are shed tumor cells that can give rise to secondary tumors (metastasis) and are commonly found in the blood of cancer patients. Dual-positive cells are circulating cells that carry markers of both tumor and immune cells and are thought to be hybrid cells resulting from rare fusions of tumor…

A multicenter study led by researchers at Cincinnati Children’s Center sheds surprising new light on why some newborns become seriously ill. Escherichia coli Some people are infected, but some people are not. It turns out that most babies have immunity thanks to bacteria-fighting antibodies they receive from their mothers. This study was published in a prestigious journal on March 11, 2026. natureSo we delve into new depths to find out why only some babies develop severe infections with common bacteria. Escherichia coli is a common bacteria that lives in the intestines of almost everyone and is the leading cause of…

Researchers told Iowa House lawmakers Wednesday that a bill that would raise tobacco taxes and strengthen pesticide monitoring requirements could help lower the state’s high cancer rates and provide more information about its causes. The House Health and Human Services Committee and the Environmental Protection Committee held a joint meeting Wednesday to hear from speakers from the University of Iowa School of Public Health about the key factors driving up Iowa’s cancer rates. These UI researchers and staff presented preliminary information collected during a year-long research project conducted through a UI partnership with the Iowa Department of Health and Human…

A series of four studies of German-speaking adults found that individuals with more pronounced dark core personalities tended to have a more pessimistic worldview. In other words, these people tended to see the world as less enjoyable, less stable, less regenerative, and less meaningful. The paper was published in. personality journal. The dark core of personality is a common underlying tendency that connects various sociophobic personality traits. It was proposed to explain why traits such as narcissism, Machiavellianism, psychopathy, everyday sadism, and meanness tend to correlate with each other. This concept suggests that these traits are not completely separate traits,…

Sildenafil – the active ingredient also sold under the name Viagra – improves symptoms in patients with Leigh syndrome. This is currently cell This journal was co-authored by researchers from the Berlin Charité – Universitätsmedizin and a team from the Heinrich-Heine University of Düsseldorf (HHU), the University Hospital Düsseldorf (UKD) and the Fraunhofer Institute for Translational Medicine and Pharmacology ITMP in Hamburg. Leigh syndrome is a rare, previously untreatable metabolic disease that begins in childhood and causes severe neurological and muscular symptoms. In a preliminary study on six patients, sildenafil showed a positive effect on the course of the disease.…

According to recent reports from multiple institutions pro swan The time of onset of hearing loss is an important determinant of patient confidence and self-reported sound localization ability (the ability to recognize and locate objects in the environment), even in people who use hearing aids or have received visual rehabilitation training, according to a study led by the Multisensory Laboratory at the Johns Hopkins Wilmer Eye Institute. The research, supported by the National Institutes of Health, focuses on the factors that shape how people with dual sensory loss (combined loss of hearing and vision) interact with their environment and identifies…

Where a woman lives has a significant impact on whether breast cancer is diagnosed early or at a later stage, according to a national analysis published in . Journal of the American College of Surgeons (jacks). The researchers found that there were significant geographic differences within rural areas across the United States, and that race and insurance status also had a significant impact on the stage of a woman’s breast cancer at the time of diagnosis. Geographical disparities were very pronounced. We found that among different rural areas across the country, a woman’s geographic residence was one of the…

With an impressive victory over blockbuster products in three head-to-head psoriasis clinical trials, UCB’s Bimzelx has conquered another strong product in psoriatic arthritis (PsA), AbbVie’s Skyrizi. The Belgian company said the Phase 3b study in 553 adults with active psoriatic arthritis met its primary objective, showing Bimzerx had a “statistically significant superiority” over Skyridi in reducing disease activity as measured by the ACR50 endpoint at week 16. ACR50 is a composite efficacy measure designated by the American College of Rheumatology that indicates a 50% or greater improvement from baseline in the number of tender or swollen joints, in addition to…

As many drug companies tally their CEO compensation for 2025, another major drug executive has amassed more than the $30 million threshold. Johnson & Johnson CEO Joaquin Duato will earn approximately $32.8 million in salary in 2025, significantly more than the $24.3 million he earned in 2024. Duato took the helm as J&J’s CEO in early 2022. By the numbers, Duato received a $1.6 million salary, the same salary he earned in 2024, and nearly $21 million in stock and option awards. Non-equity incentive compensation for the period was approximately $4.3 million. Duato collected about $600,000 in the “other compensation”…

Skyhawk Therapeutics has appointed Aaron Debs as chief commercial officer, securing the expertise of the executive who oversaw products such as Austed while at Teva. The company shared the news on the same day, saying Sunterra Pharmaceuticals also hired a new chief commercial officer. Boston-based Skyhawk has signaled it could win accelerated approval in Australia for its Huntington’s disease drug candidate SKY-0515 within 12 months. Skyhawk’s 2027 plans include launches in other markets, and the biotech company has begun preparations for commercialization, hiring Debs to lead the company. Debs previously served as chief operating officer and marketing officer for Teva’s…